Beretta F, Sanna P, Ghielmini M, Marini G, Cavalli F
Servizio Oncologico Cantonale, Ospedale San Giovanni, Bellinzona.
Schweiz Med Wochenschr. 1996 Jun 22;126(25):1107-11.
The occurrence of major neurologic disturbances is a rare complication of intrathecal cytotoxic drug administration. We describe the case of a 30-year old man with relapsed lymphoblastic lymphoma and CNS involvement who was treated by systemic chemotherapy (ESHAP) and intrathecal injections of methotrexate, cytarabine, thiotepa and hydrocortisone. Thereafter he developed persistent paraplegia with sensory and sphincteric insufficiency. The role of the drug in causing this syndrome was suspected when more common causes, such as a meningeal carcinomatosis, had been excluded by means of CNF analysis and radiological examinations. We review this and other published cases and discuss the possible pathogenesis, as well as the clinical and paraclinical findings in paraplegia following intrathecal chemotherapy. Patients particularly at risk are those who receive intrathecal chemotherapy for over CNS disease rather than as prophylaxis, those who receive several injections and patients who are concomitantly treated with radiotherapy to the brain or systemic high-dose methotrexate or cytarabine.
严重神经功能障碍的发生是鞘内注射细胞毒性药物罕见的并发症。我们描述了一名30岁复发性淋巴细胞性淋巴瘤伴中枢神经系统受累的男性病例,该患者接受了全身化疗(ESHAP)以及鞘内注射甲氨蝶呤、阿糖胞苷、噻替派和氢化可的松治疗。此后,他出现了持续性截瘫,并伴有感觉和括约肌功能不全。当通过脑脊液分析和影像学检查排除了更常见的病因,如脑膜癌病后,怀疑药物在导致该综合征中所起的作用。我们回顾了该病例及其他已发表的病例,并讨论了可能的发病机制,以及鞘内化疗后截瘫的临床和辅助检查结果。尤其有风险的患者包括那些因中枢神经系统疾病而非作为预防性治疗接受鞘内化疗的患者、接受多次注射的患者以及同时接受脑部放疗或全身大剂量甲氨蝶呤或阿糖胞苷治疗的患者。